Views: 1,363 | Downloads:
27
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Antibody Response to Hepatitis B Immunization in Infants Born to HIV-Infected Mothers
Thaithumyanon P 
,
Punnahitananda S ,
Praisuwanna P ,
Thisyakom U ,
Ruxrungtham K
,
Punnahitananda S ,
Praisuwanna P ,
Thisyakom U ,
Ruxrungtham K SANTI PUNNAHITANANDA, M.D.*,
USA THISYAKORN, M.D.*,
Objectives : To determine the antibody response of hepatitis B immunization begun at
birth in HIV -1 exposed infants.
Design : Prospective, clinical trial.
Site : King Chulalongkom Memorial Hospital, Bangkok, Thailand.
Material and Method : Seventy six infants born to HIY -1 seropositive mothers, who were
not hepatitis B carriers, received three 10 microgram doses of recombinant DNA hepatitis B vac-
cine (Engerix B, Smith Kline, Belgium) in a 0, 1 and 6 month schedule. The first dose was given
at birth. Serum hepatitis B surface antibody (Anti -HBs) was measured at age 3, 9 and 12 months.
Anti-HBs levels were determined by enzyme-linked immunoassay using the commercial kits (AUSAB
EIA diagnostic kits, Abbott Laboratories, Chicago, USA) Antibody titer
~10miU/ml
was defined as
seroconversion. HIY infection was diagnosed by a positive test of HIV antibody at age
~18
months
and/or by positive test of HIY polymerase chain reaction at age
~3
months.
Results : There were 14 HIV-1 infected (group 1) and 62 HIY-1 non infected (group 2)
infants enrolled in this study. Anti-HBs titers of group 1 infants were significantly lower than those
of groups 2 infants at both
3
and 6 months after the
3'd
dose of vaccine, (Mann Whitney
U
test,
p=0.019 and 0.001 respectively). Ten infants in group 1 and 57 infants in group 2 had anti-HBs
titer
~10
miU/ml. Their peak antibody titers were also noted at both
3
and 6 months after the
3'd
dose of vaccine. Seroconversion rates were 71.4 per cent and 91.9 per cent in group 1 and 2
infants respectively, (p
USA THISYAKORN, M.D.*,
Objectives : To determine the antibody response of hepatitis B immunization begun at
birth in HIV -1 exposed infants.
Design : Prospective, clinical trial.
Site : King Chulalongkom Memorial Hospital, Bangkok, Thailand.
Material and Method : Seventy six infants born to HIY -1 seropositive mothers, who were
not hepatitis B carriers, received three 10 microgram doses of recombinant DNA hepatitis B vac-
cine (Engerix B, Smith Kline, Belgium) in a 0, 1 and 6 month schedule. The first dose was given
at birth. Serum hepatitis B surface antibody (Anti -HBs) was measured at age 3, 9 and 12 months.
Anti-HBs levels were determined by enzyme-linked immunoassay using the commercial kits (AUSAB
EIA diagnostic kits, Abbott Laboratories, Chicago, USA) Antibody titer
~10miU/ml
was defined as
seroconversion. HIY infection was diagnosed by a positive test of HIV antibody at age
~18
months
and/or by positive test of HIY polymerase chain reaction at age
~3
months.
Results : There were 14 HIV-1 infected (group 1) and 62 HIY-1 non infected (group 2)
infants enrolled in this study. Anti-HBs titers of group 1 infants were significantly lower than those
of groups 2 infants at both
3
and 6 months after the
3'd
dose of vaccine, (Mann Whitney
U
test,
p=0.019 and 0.001 respectively). Ten infants in group 1 and 57 infants in group 2 had anti-HBs
titer
~10
miU/ml. Their peak antibody titers were also noted at both
3
and 6 months after the
3'd
dose of vaccine. Seroconversion rates were 71.4 per cent and 91.9 per cent in group 1 and 2
infants respectively, (p
Download:
PDF